Vertex Pharmaceuticals (VRTX) Other Non-Current Assets (2009 - 2026)

Vertex Pharmaceuticals' Other Non-Current Assets history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 24.73% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 24.73% YoY), while the FY2025 annual figure was $1.2 billion, up 23.75% from the prior year.
• Other Non-Current Assets was $1.3 billion for Q1 2026 at Vertex Pharmaceuticals, up from $1.2 billion in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $1.3 billion in Q1 2026 to a low of $110.7 million in Q1 2022.
• Historically, Other Non-Current Assets has averaged $734.0 million across 5 years, with a median of $895.3 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets soared 286.18% in 2023, then climbed 10.89% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $409.6 million in 2022, then surged by 118.58% to $895.3 million in 2023, then grew by 11.62% to $999.3 million in 2024, then rose by 23.75% to $1.2 billion in 2025, then grew by 1.6% to $1.3 billion in 2026.
• The last three Other Non-Current Assets figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.